GSEP
NBIX icon

Golden State Equity Partners’s Neurocrine Biosciences NBIX Stock Holding History

Golden State Equity Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-305
Closed -$40.2K – 1225
2026
Q1 		$40.2K Buy
+305
New +$40.5K ﹤0.01% 930
2024
Q4 		– Sell
-260
Closed -$30K – 710
2024
Q3 		$30K Buy
+260
New +$35.6K ﹤0.01% 606

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Golden State Equity Partners's NBIX Position: Q2 2026 in Review

Golden State Equity Partners sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 305 shares — an estimated $40.2K sold.

Golden State Equity Partners first reported a position in NBIX in Q3 2024 and held it in 2 quarters. The position peaked at $40.2K in Q1 2026. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Golden State Equity Partners reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 305 Neurocrine Biosciences shares in Q2 2026, an estimated $40.2K.
  • Golden State Equity Partners first reported a position in Neurocrine Biosciences in Q3 2024 and held it in 2 quarters.
  • Golden State Equity Partners's Neurocrine Biosciences position peaked at $40.2K in Q1 2026.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.